Personalized and Adaptive CAR-T Cell Therapy System

A next-generation CAR-T cell therapy system that leverages machine learning, CRISPR-Cas technology, and point-of-care manufacturing to provide personalized and adaptive treatment for cancer patients.

The original patent describes a method for preparing CAR-T cells with TCM as the main active component, but it has limitations in terms of scalability, adaptability, and patient specificity. The new inventive concept addresses these limitations by introducing a system that can generate CAR-T cells tailored to individual patients' tumor associated antigens, adapt to changing tumor profiles, and enable point-of-care manufacturing.

The system consists of a database of patient-specific tumor associated antigens, a CAR-T cell generator, and a machine learning module that predicts the optimal CAR-T cell composition for each patient. The CAR-T cells are engineered with modular antigen-binding domains that can be modified in-situ using CRISPR-Cas technology to adapt to changing tumor associated antigens. The point-of-care manufacturing device enables rapid and personalized CAR-T cell production, reducing the need for centralized manufacturing and logistics. Additionally, the system can be used to develop CAR-T cell-based cancer vaccines that induce durable anti-tumor immune responses.

The new claims introduce a paradigm shift in CAR-T cell therapy by integrating machine learning, CRISPR-Cas technology, and point-of-care manufacturing to provide personalized and adaptive treatment. The use of modular antigen-binding domains, CRISPR-Cas technology, and machine learning algorithms to predict optimal CAR-T cell composition are novel and non-obvious features that distinguish the new inventive concept from the original patent.

Alternative embodiments of the inventive concept could include using different machine learning algorithms, integrating additional biomarkers or genomic data, or incorporating other gene editing technologies. Variations of the point-of-care manufacturing device could include different microfluidic systems, user interfaces, or miniaturized CAR-T cell generators.

The personalized and adaptive CAR-T cell therapy system has the potential to revolutionize the cancer treatment landscape, providing a more effective and targeted approach to cancer therapy. The market potential is significant, with applications in various cancer types, including solid tumors and hematological malignancies. The system could also be used for cancer vaccine development, further expanding its commercial potential.